CARDIFF ONCOLOGY, INC. Operating Leases, Rent Expense, Net
CARDIFF ONCOLOGY, INC. (CRDF) reported Operating Leases, Rent Expense, Net of $731.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeasesRentExpenseNet · last filed 2019-03-06
- CARDIFF ONCOLOGY, INC. operating leases, rent expense, net for fiscal 2018 was $731.00K, a 10.26% increase from fiscal 2017.
- CARDIFF ONCOLOGY, INC. operating leases, rent expense, net for fiscal 2017 was $663.00K, a 10.13% increase from fiscal 2016.
- CARDIFF ONCOLOGY, INC. operating leases, rent expense, net for fiscal 2016 was $602.00K, a 27.81% increase from fiscal 2015.
- CARDIFF ONCOLOGY, INC. operating leases, rent expense, net for fiscal 2015 was $471.00K, a 49.52% increase from fiscal 2014.
| Period end | Operating Leases, Rent Expense, Net 12 month | Operating Leases, Rent Expense, Net 12 month as first filed |
|---|---|---|
| 2018-12-31 | $731.00K 10-K · filed 2019-03-06 | |
| 2017-12-31 | $663.00K 10-K · filed 2019-03-06 | |
| 2016-12-31 | $602.00K 10-K · filed 2018-02-26 | |
| 2015-12-31 | $471.00K 10-K · filed 2017-03-15 | |
| 2014-12-31 | $315.00K 10-K · filed 2017-03-15 | |
| 2013-12-31 | $294.00K 10-K · filed 2016-03-10 | |
| 2012-12-31 | $270.00K 10-K · filed 2015-03-12 | $202.00K 10-K · filed 2013-04-01 |
| 2011-12-31 | $164.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |